Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[To enhance the immunogenecity of CEA, we developed a fusion gene (CRT-TAT-DeltaCEA) of the TAT protein transduction domain (PTD) and calreticulin (CRT) with human CEA devoid of its signal sequences (DeltaCEA) and evaluated anti-tumor immunity using RNA-pulsed dendritic cell (DC) vaccination.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP275423.RAYXRcrc-mA6Q7XKDcOmPPnPcfB5OPeEGODXSwYH7SuDA130_assertion description "[To enhance the immunogenecity of CEA, we developed a fusion gene (CRT-TAT-DeltaCEA) of the TAT protein transduction domain (PTD) and calreticulin (CRT) with human CEA devoid of its signal sequences (DeltaCEA) and evaluated anti-tumor immunity using RNA-pulsed dendritic cell (DC) vaccination.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP275423.RAYXRcrc-mA6Q7XKDcOmPPnPcfB5OPeEGODXSwYH7SuDA130_provenance.
• NP453743.RAAA1AbWnStV0u8u3YG4oCmdPfmRWXvoYd_8Y0g3B6sJ4130_assertion description "[To enhance the immunogenecity of CEA, we developed a fusion gene (CRT-TAT-DeltaCEA) of the TAT protein transduction domain (PTD) and calreticulin (CRT) with human CEA devoid of its signal sequences (DeltaCEA) and evaluated anti-tumor immunity using RNA-pulsed dendritic cell (DC) vaccination.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP453743.RAAA1AbWnStV0u8u3YG4oCmdPfmRWXvoYd_8Y0g3B6sJ4130_provenance.
• NP719058.RAvEzU4TD7t3Owagz3yk7Bee0TG_SxbxTtfRCbH-G6PRw130_assertion description "[To enhance the immunogenecity of CEA, we developed a fusion gene (CRT-TAT-DeltaCEA) of the TAT protein transduction domain (PTD) and calreticulin (CRT) with human CEA devoid of its signal sequences (DeltaCEA) and evaluated anti-tumor immunity using RNA-pulsed dendritic cell (DC) vaccination.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP719058.RAvEzU4TD7t3Owagz3yk7Bee0TG_SxbxTtfRCbH-G6PRw130_provenance.
• NP931562.RARVEgpNyYp8Jg3waNNHE46doGMxOGjZ2JA7_96gbGY8c130_assertion description "[To enhance the immunogenecity of CEA, we developed a fusion gene (CRT-TAT-DeltaCEA) of the TAT protein transduction domain (PTD) and calreticulin (CRT) with human CEA devoid of its signal sequences (DeltaCEA) and evaluated anti-tumor immunity using RNA-pulsed dendritic cell (DC) vaccination.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP931562.RARVEgpNyYp8Jg3waNNHE46doGMxOGjZ2JA7_96gbGY8c130_provenance.
• assertion description "[To enhance the immunogenecity of CEA, we developed a fusion gene (CRT-TAT-DeltaCEA) of the TAT protein transduction domain (PTD) and calreticulin (CRT) with human CEA devoid of its signal sequences (DeltaCEA) and evaluated anti-tumor immunity using RNA-pulsed dendritic cell (DC) vaccination.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[To enhance the immunogenecity of CEA, we developed a fusion gene (CRT-TAT-DeltaCEA) of the TAT protein transduction domain (PTD) and calreticulin (CRT) with human CEA devoid of its signal sequences (DeltaCEA) and evaluated anti-tumor immunity using RNA-pulsed dendritic cell (DC) vaccination.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP279920.RAW6EfpsLqOxmolsp1Qpr6hNNdh35nyBR6M3xtY_4iluE130_assertion description "[To enhance the immunogenecity of CEA, we developed a fusion gene (CRT-TAT-DeltaCEA) of the TAT protein transduction domain (PTD) and calreticulin (CRT) with human CEA devoid of its signal sequences (DeltaCEA) and evaluated anti-tumor immunity using RNA-pulsed dendritic cell (DC) vaccination.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP279920.RAW6EfpsLqOxmolsp1Qpr6hNNdh35nyBR6M3xtY_4iluE130_provenance.
• NP722888.RAxowXTI7C1IeFCMWKYNHoOBgWa9ZbzaIbRZjhobowCwE130_assertion description "[To enhance the immunogenecity of CEA, we developed a fusion gene (CRT-TAT-DeltaCEA) of the TAT protein transduction domain (PTD) and calreticulin (CRT) with human CEA devoid of its signal sequences (DeltaCEA) and evaluated anti-tumor immunity using RNA-pulsed dendritic cell (DC) vaccination.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP722888.RAxowXTI7C1IeFCMWKYNHoOBgWa9ZbzaIbRZjhobowCwE130_provenance.
• assertion description "[To enhance the immunogenecity of CEA, we developed a fusion gene (CRT-TAT-DeltaCEA) of the TAT protein transduction domain (PTD) and calreticulin (CRT) with human CEA devoid of its signal sequences (DeltaCEA) and evaluated anti-tumor immunity using RNA-pulsed dendritic cell (DC) vaccination.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP947353.RACZOUKf7BDfP5ZXAfT1OPLiuagmYqcO9W1JDqQgz3K_w130_assertion description "[To enhance the immunogenecity of CEA, we developed a fusion gene (CRT-TAT-DeltaCEA) of the TAT protein transduction domain (PTD) and calreticulin (CRT) with human CEA devoid of its signal sequences (DeltaCEA) and evaluated anti-tumor immunity using RNA-pulsed dendritic cell (DC) vaccination.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP947353.RACZOUKf7BDfP5ZXAfT1OPLiuagmYqcO9W1JDqQgz3K_w130_provenance.
• NP723214.RAigT3a22HwxdCCsCZviGaVu3Pbl2z9bDUpG8uvrSNbMc130_assertion description "[To enhance the immunogenecity of CEA, we developed a fusion gene (CRT-TAT-DeltaCEA) of the TAT protein transduction domain (PTD) and calreticulin (CRT) with human CEA devoid of its signal sequences (DeltaCEA) and evaluated anti-tumor immunity using RNA-pulsed dendritic cell (DC) vaccination.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP723214.RAigT3a22HwxdCCsCZviGaVu3Pbl2z9bDUpG8uvrSNbMc130_provenance.
• NP309522.RANDNryPbSvf7NmGHCiNQyollV8HzVv18-kVGkmgiMXV4130_assertion description "[To enhance the immunogenecity of CEA, we developed a fusion gene (CRT-TAT-DeltaCEA) of the TAT protein transduction domain (PTD) and calreticulin (CRT) with human CEA devoid of its signal sequences (DeltaCEA) and evaluated anti-tumor immunity using RNA-pulsed dendritic cell (DC) vaccination.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP309522.RANDNryPbSvf7NmGHCiNQyollV8HzVv18-kVGkmgiMXV4130_provenance.
• NP694541.RAGw574XByphc0JufQDrgsOYZwcPXBS907mSB6HFOxXnI130_assertion description "[To enhance the immunogenecity of CEA, we developed a fusion gene (CRT-TAT-DeltaCEA) of the TAT protein transduction domain (PTD) and calreticulin (CRT) with human CEA devoid of its signal sequences (DeltaCEA) and evaluated anti-tumor immunity using RNA-pulsed dendritic cell (DC) vaccination.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP694541.RAGw574XByphc0JufQDrgsOYZwcPXBS907mSB6HFOxXnI130_provenance.
• NP694543.RAFgiJl5wj217NOvtxeSfqv06rnAE3jkHr_J27_koe4WY130_assertion description "[To enhance the immunogenecity of CEA, we developed a fusion gene (CRT-TAT-DeltaCEA) of the TAT protein transduction domain (PTD) and calreticulin (CRT) with human CEA devoid of its signal sequences (DeltaCEA) and evaluated anti-tumor immunity using RNA-pulsed dendritic cell (DC) vaccination.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP694543.RAFgiJl5wj217NOvtxeSfqv06rnAE3jkHr_J27_koe4WY130_provenance.
• NP694544.RAJFHotZ5N2y6O4-J8bPbwEWQHzqvRHwnYIbpt4UA3Sn4130_assertion description "[To enhance the immunogenecity of CEA, we developed a fusion gene (CRT-TAT-DeltaCEA) of the TAT protein transduction domain (PTD) and calreticulin (CRT) with human CEA devoid of its signal sequences (DeltaCEA) and evaluated anti-tumor immunity using RNA-pulsed dendritic cell (DC) vaccination.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP694544.RAJFHotZ5N2y6O4-J8bPbwEWQHzqvRHwnYIbpt4UA3Sn4130_provenance.
• NP694542.RA0WWj2q55m5gRQZqdaTfSeZk9TTpvgMm9usQai5YZ5gc130_assertion description "[To enhance the immunogenecity of CEA, we developed a fusion gene (CRT-TAT-DeltaCEA) of the TAT protein transduction domain (PTD) and calreticulin (CRT) with human CEA devoid of its signal sequences (DeltaCEA) and evaluated anti-tumor immunity using RNA-pulsed dendritic cell (DC) vaccination.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP694542.RA0WWj2q55m5gRQZqdaTfSeZk9TTpvgMm9usQai5YZ5gc130_provenance.